Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Chemotherapy and Radiotherapy
  •  Hematology
  •  Immunology
  •  Gynecological Cancers
  •  Colon Cancer
  •  Endoscopy Methods
  •  Cervical Cancer
  •  Prostate Cancer

Abstract

Citation: Clin Oncol. 2024;9(1):2061.DOI: 10.25107/2474-1663.2061

MC1R Common Variants and the 10-Year Survival after Melanoma in Polish Population

Dębniak T, Baszuk P, Rowińska K, Feherpataky M, Boer M, Kiedrowicz M, Marchlewicz M, Cybulski C, Jakubowska A, Huzarski T, Lener M, Dębniak A, Białożyt J, Bielawska I, Lubiński J and Gronwald J

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Poland
Department of Clinical Genetics and Pathology, University of Zielona Góra, Poland
Department of Skin Diseases and Venerology PUM, Poland
West Pomeranian Oncology Center, Szczecin, Poland

*Correspondance to: Tadeusz Dębniak 

 PDF  Full Text Research Article | Open Access

Abstract:

Melanoma represents a significant health care burden. The Melanocortin-1-Receptor (MC1R) gene is highly polymorphic, it’s pigmentary and non-pigmentary biological functions may be important for survival. Herein we report the 10-year survival of our cohort of 1032 melanoma patients depending on their MC1R status. The p.D84E, p.R142H, p.R151C, p.I155T, p.R160W and p.D294H MC1R variants were evaluated. All study participants were followed-up since the date of diagnosis to 2022 or until death. Statistical analyses included univariable and multivariable COX regression models. In the entire cohort no significant differences of overall survival were observed in relation to the MC1R status. In subgroup of men patients carrying any of the MC1R variant have worse survival than subjects with wild type (HR=2.04; 95% CI=1.04-3.98; p=0.037 and HR=2.05; 95% CI=1.05-4.01; p=0.035 for univariable and multivariable models respectively). Hazard ratios were significantly higher among older (≥ 50) patients (HR=4.14; 95% CI=2.20-7.80; p<0.001). Men compared to women have worse survival (HR 1.65; 95% CI=1.08-2.52; p=0.021). In conclusion- any possible MC1R effect on disease course is not strong, may differ among populations and may lead to worse prognosis among men. Due to a paucity of literature data additional prospective studies focused on possible association of MC1R mutations and melanoma prognosis are needed.

Keywords:

Melanoma; MC1R; Survival; Genetics

Cite the Article:

Dębniak T, Baszuk P, Rowińska K, Feherpataky M, Boer M, Kiedrowicz M, et al. MC1R Common Variants and the 10-Year Survival after Melanoma in Polish Population. Clin Oncol. 2024;9:2061..

Search Our Journal

Journal Indexed In

Articles in PubMed

Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Expression of the Oncoprotein E5 from Human papillomavirus and miR-203 in Pre-Cancer Lesions and Cervical Cancer
 Abstract  PDF  Full Text
Immunohistochemistry Biomarkers in Bladder Cancer: The Old and the New Immunohistochemistry Markers in Bladder Cancer
 Abstract  PDF  Full Text
View More...